Evidence map›Paper›PMID 34916688›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2021

[Assessment of lymphocytic function

D Yang, X N Zhou, S Wang, X L Wang, Y H Yuan, H B Yang, H Z Geng, B Peng, Z B Li, B Li and 1 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

D YangDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University Beijing Key Laboratory of Therapeutic Vaccines, Beijing 100038, China.
X N ZhouDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University Beijing Key Laboratory of Therapeutic Vaccines, Beijing 100038, China.
S WangDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University Beijing Key Laboratory of Therapeutic Vaccines, Beijing 100038, China.
X L WangDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University Beijing Key Laboratory of Therapeutic Vaccines, Beijing 100038, China.
Y H YuanDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University Beijing Key Laboratory of Therapeutic Vaccines, Beijing 100038, China.
H B YangDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University Beijing Key Laboratory of Therapeutic Vaccines, Beijing 100038, China.
H Z GengHebei Bio-High Technology Company Limited, Shijiazhuang 050035, China.
B PengHebei Bio-High Technology Company Limited, Shijiazhuang 050035, China.
Z B LiHebei Bio-High Technology Company Limited, Shijiazhuang 050035, China.
B LiHebei Bio-High Technology Company Limited, Shijiazhuang 050035, China.
J RenDepartment of Oncology, Beijing Shijitan Hospital, Capital Medical University Beijing Key Laboratory of Therapeutic Vaccines, Beijing 100038, China.
Beijing Shijitan Hospital · CNHebei Science and Technology Department · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the activation function of specific tumor polypeptide for dendritic cell vaccine on lymphocytes proliferation, production of cytokines and killing activity

methodsPeripheral blood dendritic cells (DC) and cytokine-induced killer (CIK) were isolated and cultured by adherent culture method; CCK-8 method was used to assess the proliferation function of lymphocytes and the killing function of lymphocytes to tumor cells; enzyme-linked immunospot assay method was used to evaluate the secretion function of cytokines. The experiment was divided into tumor polypeptide group (peptide with DC-CIK), DC-CIK group and CIK group.

resultsWith presence of interleukin-2 (IL-2) in the culture system, the lymphocyte proliferation of the three groups was obvious. The absorbance at 450 nm of tumor polypeptide group was significantly higher than that of CIK group at the time points day 4 and day 6 (day 4:

conclusionTumor peptide combined with dendritic cells can improve the proliferation activity of CIK cells

Indexed as

Dendritic CellsPeptidesPeptidesCIK cellsCytokinesCytotoxicityDendritic cellsProliferationTumor polypeptides

Identifiers

PMID34916688
PMCPMC8695145
OpenAlexW4200628470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.